Keros Therapeutics Inc. Common Stock
KROSUnited States
5 filed reports · 220 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 775 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 521 | Dec 2025 |
Financial data
220 concepts · 1,296 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial210 concepts · 1,143 facts · Dec 2020 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
- Net income loss12 · Mar 2024 to Jun 2026
- Stockholders equity (US GAAP)12 · Mar 2024 to Jun 2026
- Stock issued during period value stock options exercised12 · Mar 2024 to Jun 2026
- Allocated share based compensation expense11 · Jun 2024 to Jun 2026
- Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
- Common stock par or stated value per share11 · Jun 2024 to Jun 2026
- Dividend income operating11 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
- Income tax expense benefit11 · Jun 2024 to Jun 2026
- Incremental common shares attributable to share based payment arrangements11 · Jun 2024 to Jun 2026
- Net income loss available to common stockholders basic11 · Jun 2024 to Jun 2026
- Net income loss available to common stockholders diluted11 · Jun 2024 to Jun 2026
- Nonoperating income expense11 · Jun 2024 to Jun 2026
- Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
- Operating income loss11 · Jun 2024 to Jun 2026
- Other nonoperating income expense11 · Jun 2024 to Jun 2026
- Research and development expense11 · Jun 2024 to Jun 2026
- Restricted cash11 · Jun 2024 to Jun 2026
- Revenue11 · Jun 2024 to Jun 2026
- Capital expenditures incurred but not yet paid10 · Sep 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect10 · Sep 2024 to Jun 2026
- Depreciation10 · Sep 2024 to Jun 2026
Segment9 concepts · 109 facts · Jun 2024 to Jun 2026
- Research and development expense45 · Jun 2024 to Jun 2026
- Compensation expense excluding cost of good and service sold11 · Jun 2024 to Jun 2026
- Net income loss11 · Jun 2024 to Jun 2026
- Revenue11 · Jun 2024 to Jun 2026
- Segment reporting other item amount11 · Jun 2024 to Jun 2026
- Allocated share based compensation expense8 · Jun 2024 to Jun 2026
- Depreciation4 · Jun 2024 to Sep 2025
- Income tax expense benefit4 · Jun 2024 to Sep 2025
- Investment income dividend4 · Jun 2024 to Sep 2025
Product1 concepts · 44 facts · Jun 2024 to Jun 2026
- Revenue44 · Jun 2024 to Jun 2026
Segments
153 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 109 facts
- Reportable109 · Jun 2024 to Jun 2026
Product or service4 members · 44 facts
- License11 · Jun 2024 to Jun 2026
- License Revenue11 · Jun 2024 to Jun 2026
- Service11 · Jun 2024 to Jun 2026
- Service Other11 · Jun 2024 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.